To elaborate on the concept of superhuman vaccine immunity:
Each of the 3 examples in our piece are for different reasons. 1. HPV—best, since the human response is weak 2. Tetanus—small amounts of toxin don't elicit strong response) 3. H Flu—the bacterium is sugar coated
2/
This is different from vaccine efficacy.
Take measles. The natural human response to infection provides durable efficacy but the vaccine requires multiple shots and is without lifelong protection. 3/
Superhuman vaccine = superior to typical human response to natural infection
The #SARSCoV2 neutralizing antibody response to mRNA vaccines has exceeded that of many convalescent patients by orders of magnitude @NEJMbit.ly/33ys84T 4/
The natural human response to #COVID19 infection leaves many patients without a full and/or durable immune response, as nicely depicted (G=IgG, B=B cells, 4=CD4, 8=CD8, A=IgA) biorxiv.org/content/10.110… Figure 5C @profshanecrotty and colleagues 5/
Several #SARSCoV2 reinfections have been documented in patients without a sufficient IgG antibody response to the primary infection bnonews.com/index.php/2020… 6/
There are still many unknowns about the mRNA (and other platform) #SARSCoV2 vaccines with respect to durability, sterilization immunity (that would prevent transmission) and the role of T cells. 7/
In sum, the results to date suggest #SARSCoV2's spike protein lays the foundation for a potent vaccine-induced immune response that will turn out to be superior to that derived from natural infections. 8/
I recently spoke to @DrPaulOffit about the concept of a superhuman vaccine immune response medscape.com/viewarticle/93…
He highlighted the #SARSCoV2 inhibition of our interferon response and this point👇
And cited the 3 prototypic examples
• • •
Missing some Tweet in this thread? You can try to
force a refresh
New US Covid genomic surveillance
The KP.3.1.1 variant is on the move to become dominant, more of a challenge to our immune response than KP.3 and prior variants (especially without new KP.2 booster when we need it for high-risk individuals)
It's the deletion 31/31 that makes the KP.3.1.1 spike different, but otherwise 2 mutations away from KP.2 (R346T and Q493E)
Buckle up; this wave isn't over yet d/t KP.3.1.1's emergence
We've known about KP.3's marked growth advantage since April and could have made the call then to make the new booster. That would have been aligned well with the current wave (available in July) 2/5 erictopol.substack.com/p/are-we-flirt…
But the FDA has tried to force fit Covid into an annual shot like flu, even though all data tells us it doesn't follow an annual pattern. Even the CDC acknowledges this now
3/5cdc.gov/ncird/whats-ne…
New CDC genomic data shows continued rise of the KP.3 variant that accounts for 1 of 3 Covid cases.
LB.1 is gaining, too, as JN.1 fades away
This variant growth advantage plot by @BenjMurrell (H/T @siamosolocani) shows why this is the case. Note KP.3 is the one at far left w/ almost 3-fold advantage to JN.1.
Reinforces why the decision to develop the KP.2 vaccine booster (instead of JN.1) was a good one
Spike mutation map to show the differences betweem KP.3 and JN.1 (and LB.1, KP.2)
The connection between #SARSCoV2 and neurodegeneration
@TheLancetNeuro
Quotes below: 1. SARS-CoV-2 infection should be considered as a risk factor for Alzheimer’s disease, even though the distinction between causation versus disease acceleration is not clear.thelancet.com/journals/laneu…
2. Inflammation in patients with COVID-19, and controlled experiments show prolonged neuro-inflammation after mild SARS-CoV-2 infection
in macaques.
3. A direct correlation has been reported
between prior SARS-CoV-2 infection and increased risk
of Alzheimer’s disease (figure).
4. So far, the estimated lifetime cumulative risk of dementia due to hospitalisation for any viral infection is 1·48 (95% CI 1·15–1·91).
Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved @US_FDA last year. It doesn't look good.